Real-World Study Evaluates Saxenda® Safety and Effectiveness for Obesity in Taiwan

Obesity is a growing global health challenge, significantly increasing the risk of numerous comorbidities like type 2 diabetes and cardiovascular disease. Liraglutide, marketed as Saxenda®, is a GLP-1 receptor agonist approved for chronic weight management. Despite its established efficacy from controlled trials, there remains a need for real-world evidence on its safety and effectiveness in diverse populations, particularly in specific regional contexts like Taiwan. This study addresses the knowledge gap regarding how Saxenda® performs in routine clinical practice among Taiwanese adults and adolescents with obesity.

While specific quantitative results on adverse events or weight loss are not provided in this abstract, the study's design aimed to comprehensively assess the real-world safety and effectiveness of Liraglutide (Saxenda®) in a Taiwanese population. The primary outcome measured was the incidence of adverse events (AEs) by preferred term, tracked from baseline (week 0) to week 26. This non-interventional approach allows for the collection of data reflecting actual clinical usage patterns and patient experiences outside of highly controlled trial settings. The study's most important objective was to quantify the incidence of adverse events (AEs) in patients receiving Saxenda® for 26 weeks under routine clinical care, providing crucial safety data for post-marketing surveillance.